Study guide

7.1 Coronary Artery Disease & Acute Coronary Syndromes

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

7.1 Coronary Artery Disease & Acute Coronary Syndromes

Key Takeaways Explain This Topic AI

Primary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for ST-elevation myocardial infarction (STEMI) when it can be performed within 90 minutes of first medical contact at a PCI-capable facility, or within 120 minutes if transfer is required.

Fibrinolytic therapy (e.g., alteplase, tenecteplase) is indicated for STEMI within 30 minutes of hospital arrival (door-to-needle time) when transfer to a PCI center cannot achieve reperfusion within 120 minutes and there are no absolute contraindications.

Right ventricular infarction occurs in 30% to 40% of inferior STEMIs (right coronary artery occlusion) and presents with hypotension, jugular venous distension, and clear lung fields; management requires IV normal saline boluses while avoiding preload-reducing agents such as nitrates, opioids, and diuretics.

TIMI risk score >=3 in patients with non-ST-elevation acute coronary syndrome (NSTEMI/Unstable Angina) indicates high risk and warrants an early invasive management strategy (coronary angiography within 24 hours).

Mechanical complications post-myocardial infarction typically present 3 to 14 days after the index event: papillary muscle rupture causes acute severe mitral regurgitation with giant v waves, interventricular septum rupture causes a harsh holosystolic murmur with oxygen saturation step-up in the right ventricle, and free wall rupture causes cardiac tamponade and PEA.

Last updated: July 2026

Coronary Artery Disease & Acute Coronary Syndromes

Coronary artery disease (CAD) remains the leading cause of mortality worldwide. On USMLE Step 2 CK, candidates are evaluated on their ability to differentiate stable ischemic heart disease from acute coronary syndromes (ACS), interpret electrocardiograms (EKGs), select appropriate non-invasive diagnostic testing, and execute time-sensitive pharmacologic and invasive reperfusion strategies.

Stable Ischemic Heart Disease & Diagnostic Workup

Stable angina pectoris presents as predictable, exertional substernal chest pressure that is relieved by rest or sublingual nitroglycerin within 5 minutes. The underlying pathophysiology is stable atherosclerotic plaque producing fixed luminal narrowing (typically ≥ 70 % \ge 70\% ≥ 70% obstruction).

When evaluating chest pain, clinicians first establish the pre-test probability of CAD based on age, sex, and symptom character (typical vs. atypical vs. non-cardiac).

Diagnostic Testing Algorithm

Patient Profile & Baseline EKG Recommended Initial Test Clinical Rationale & Pearls

Low-to-Intermediate Risk , normal resting EKG, able to exercise Exercise ECG Stress Test Positive test: ≥ 1 mm \ge 1\text{ mm} ≥ 1 mm horizontal or downsloping ST depression.

Intermediate-to-High Risk , uninterpretable EKG (LBBB, ST changes, digoxin, LVH) Pharmacologic Stress Imaging (Nuclear MPI or Echo) Adenosine/Regadenoson (coronary vasodilators) or Dobutamine (inotropic/chronotropic). Avoid adenosine in severe asthma.

Prior CABG / Stent or uninterpretable exercise capacity Stress Echocardiography or Myocardial Perfusion Imaging (MPI) Detects inducible wall motion abnormalities or reversible perfusion defects.

Low-to-Intermediate Risk , acute chest pain, low troponin Coronary Computed Tomography Angiography (CCTA) High negative predictive value to rule out CAD.

High Pre-test Probability or severe refractory angina Invasive Coronary Angiography Diagnostic and therapeutic gold standard allowing percutaneous intervention.

Important Test-Taking Pearl: If a patient has a Left Bundle Branch Block (LBBB) or a ventricular paced rhythm, exercise stress testing and dobutamine stress testing are unreliable due to septal motion artifacts. Regadenoson or adenosine myocardial perfusion imaging is the diagnostic procedure of choice.

Acute Coronary Syndromes: Pathophysiology & Risk Stratification

Acute coronary syndromes represent a spectrum of acute myocardial ischemia resulting from atheromatous plaque rupture or erosion with superimposed thrombosis. ACS is divided into three distinct entities based on cardiac biomarkers and EKG findings:

Unstable Angina (UA): Ischemic symptoms at rest, new-onset severe angina, or crescendo angina. Cardiac troponins are negative , and EKG may show ST depression or T-wave inversion.

Non-ST-Elevation Myocardial Infarction (NSTEMI): Symptoms similar to UA, but with elevated cardiac troponins indicating myocardial necrosis. EKG displays ST depressions, T-wave inversions, or non-specific changes.

ST-Elevation Myocardial Infarction (STEMI): Transmural myocardial ischemia causing ST-elevation in ≥ 2 \ge 2 ≥ 2 contiguous leads or a new LBBB, accompanied by troponin elevation.

Cardiac Biomarker Kinetics

Cardiac Troponin I and T: Most sensitive and specific. Rise at 3–6 hours, peak at 18–24 hours, and remain elevated for 7–10 days.

CK-MB (Creatine Kinase-MB): Rises at 4–6 hours, peaks at 18–24 hours, and returns to baseline within 48–72 hours. Useful for detecting early re-infarction if chest pain recurs 3–4 days post-MI.

Risk Stratification in UA/NSTEMI

The TIMI (Thrombolysis in Myocardial Infarction) Risk Score stratifies 14-day mortality and ischemic risk in UA/NSTEMI. One point is assigned for each criterion (Age ≥ 65 \ge 65 ≥ 65 , ≥ 3 \ge 3 ≥ 3 CAD risk factors, known CAD stenosis ≥ 50 % \ge 50\% ≥ 50% , ASA use in past 7 days, severe angina ≤ 24 hours \le 24\text{ hours} ≤ 24 hours , elevated cardiac markers, ST deviation ≥ 0.5 mm \ge 0.5\text{ mm} ≥ 0.5 mm ).

TIMI Score 0–2 (Low Risk): Ischemia-guided medical management.

TIMI Score ≥ 3 \ge 3 ≥ 3 (High Risk): Early invasive strategy with coronary angiography within 24 hours .

  • Acute Emergency Management & Reperfusion Protocols
  • Initial Medical Management (NSTEMI / UA / STEMI)

Aspirin: Chewable non-enteric coated 162–325 mg immediately, followed by 81 mg daily indefinitely.

P2Y12 Inhibitor: Loading dose of ticagrelor (180 mg) or prasugrel (60 mg) or clopidogrel (600 mg). Combined with aspirin for Dual Antiplatelet Therapy (DAPT) for at least 12 months post-PCI.

Anticoagulation: Unfractionated heparin (UFH) drip or low-molecular-weight heparin ( enoxaparin 1 mg/kg SC q12h) or fondaparinux.

Nitrates: Sublingual or IV nitroglycerin for pain and preload reduction. Absolute Contraindications: Right ventricular infarction, severe aortic stenosis, or phosphodiesterase-5 inhibitor use ( sildenafil within 24 hours, tadalafil within 48 hours).

Beta-Blockers: Oral metoprolol or carvedilol within 24 hours. Avoid in acute heart failure, cardiogenic shock, or severe bradycardia.

High-Intensity Statin: Atorvastatin 80 mg or rosuvastatin 40 mg initiated immediately regardless of baseline LDL level.

ACE Inhibitors / ARBs: Initiated within 24 hours, especially in anterior MI, LVEF < 40 % <40\% < 40% , or hypertension.

STEMI EKG Localization & Reperfusion Timing

EKG Leads Affected Wall Occluded Coronary Artery Clinical Notes & Complications

V1–V4 Anterior / Septal Left Anterior Descending (LAD) Highest risk of acute LV failure, cardiogenic shock, and free wall rupture.

I, aVL, V5–V6 Lateral Left Circumflex (LCX) May present with isolated lateral ST elevations.

II, III, aVF Inferior Right Coronary Artery (RCA) High risk of AV block and associated Right Ventricular (RV) Infarction .

V1–V3 ST depression with tall R waves Posterior Posterior Descending Artery (PDA) Confirm with ST elevation in posterior leads V7–V9.

Right Ventricular Infarction Management: Occurs in up to 40% of inferior MIs. Presenting features include hypotension, elevated JVD, and clear lungs. Diagnostic confirmation requires ST elevation in right-sided leads V3R–V4R . Treatment: Aggressive IV isotonic saline volume expansion to maintain RV preload. Avoid nitrates, opioids, and diuretics.

STEMI Reperfusion Guidelines

Primary PCI (Preferred): First medical contact-to-balloon time ≤ 90 minutes \le 90\text{ minutes} ≤ 90 minutes at a PCI-capable facility, or ≤ 120 minutes \le 120\text{ minutes} ≤ 120 minutes if transfer to a PCI center is required.

Fibrinolytic Therapy: Indicated if transfer to PCI cannot be achieved within 120 minutes. Door-to-needle time must be ≤ 30 minutes \le 30\text{ minutes} ≤ 30 minutes . Absolute contraindications include prior intracranial hemorrhage, active internal bleeding, ischemic stroke within 3 months, or suspected aortic dissection.

Post-Myocardial Infarction Complications Timeline

Timeframe Complication Clinical Presentation Management Strategy

First 24 Hours Ventricular Arrhythmias (VF/VT) Most common cause of pre-hospital death. Sudden cardiac arrest. Defibrillation, amiodarone, ACLS protocol.

1 to 3 Days Peri-infarction Pericarditis Pleuritic chest pain, pericardial friction rub, diffuse ST elevation. High-dose Aspirin (650 mg tid) . Avoid NSAIDs and steroids.

3 to 14 Days Papillary Muscle Rupture Acute severe Mitral Regurgitation , sudden pulmonary edema, holosystolic murmur at apex radiating to axilla, giant v waves on PCWP. Emergency surgical valve repair/replacement, intra-aortic balloon pump (IABP).

3 to 14 Days Interventricular Septum Rupture Biventricular failure, harsh holosystolic murmur at left lower sternal border with thrill, oxygen saturation step-up from RA to RV . Emergency surgical closure, IABP.

3 to 14 Days Free Wall Rupture Sudden electromechanical dissociation (PEA), pericardial tamponade (Beck triad), death. Pericardiocentesis, emergency surgery.

>2 Weeks to Months Left Ventricular Aneurysm Persistent ST-segment elevation weeks post-MI, heart failure, mural thrombus causing ischemic stroke. Anticoagulation, surgical resection if symptomatic.

2 to 10 Weeks Dressler Syndrome Autoimmune pericarditis, fever, leukocytosis, elevated ESR/CRP. NSAIDs plus Colchicine .